Atropine vs Isoprenaline in the Invasive Diagnosis of Arrhythmias

Last updated: October 9, 2023
Sponsor: Medical University of Lodz
Overall Status: Active - Not Recruiting

Phase

N/A

Condition

Dysrhythmia

Atrial Flutter

Arrhythmia

Treatment

Comparison of atropine and isoprenaline

Clinical Study ID

NCT06082388
RNN/327/20/KE
  • Ages > 18
  • All Genders

Study Summary

During electrophysiological study (EPS) multiple drugs are used to reveal arrhythmias and/or conductive system disorders. Two most often used agents are atropine and isoprenaline. Due to their distinct pharmacological properties, they are affecting myocardium in different manner. Those dissimilarities can affect the EPS course and long-term prognosis. The aim of presented study is to evaluate the optimal protocol of pharmacotherapy during EPS.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Patients with indication for electrophysiological study according to presentguidelines of European Society of Cardiology

Exclusion

Exclusion Criteria:

  • Not willing or incapable to give written informed consent.
  • Previous diagnosed ventricle tachycardia or fibrillation
  • Previous diagnosed atrial fibrillation or flutter
  • Glaucoma (contraindication for atropine)

Study Design

Total Participants: 200
Treatment Group(s): 1
Primary Treatment: Comparison of atropine and isoprenaline
Phase:
Study Start date:
November 09, 2023
Estimated Completion Date:
December 31, 2025

Study Description

Electrophysiological study (EPS) is essential tool for heart rhythm disorders diagnostic. Inducibility of arrhythmia before ablation to confirm the diagnosis and inability to do so after the procedure is crucial for long-term success. Multiple drugs are used to reveal arrhythmias and/or conductive system disorders. Two most often used are atropine and isoprenaline. Atropine is a natural, selective antagonist of cholinergic receptors M1 and M2. It reverses the inhibitory effect of vagal nerve on myocardium. This improves sinus node automatism and conduction in atrioventricular node. Isoprenaline is a preferential agonist of beta-1-adrenergic receptors. It has bathmotropic and chronotropic effect. During daily clinical practice those two drugs are often used interchangeably. However, differences in pharmacokinetics and pharmacodynamics may affect the results. There are lack of data directly comparing those two agents. There are isolated evidences that arrhythmia inducibility rate after the ablation differs between those two drugs. This may lead to the misconception of ablation as successful. The aim of presented study is to evaluate the optimal protocol of pharmacotherapy during EPS.

Connect with a study center

  • Department of Electrocardiology Medical University of Lodz

    Lodz, 93-216
    Poland

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.